Rodney Kb Young - 03 Mar 2026 Form 4 Insider Report for RAPT Therapeutics, Inc. (RAPT)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: RAPT
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 08:58:17 UTC
Prior SEC filing: 24 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Rodney Young

Key filing fact

Rodney Kb Young filed Form 4 for RAPT Therapeutics, Inc. (RAPT) on 05 Mar 2026.

Key facts

This page summarizes Rodney Kb Young's Form 4 filing for RAPT Therapeutics, Inc. (RAPT).
8 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 08:58.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001337831 Primary reporting owner

Young Rodney KB

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO
Signature: /s/ Rodney Young
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -3,304
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -17,501
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,501
Exercise price: $12.56
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -7,500
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $12.56
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,125
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,125
Exercise price: $12.56
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,501
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,501
Exercise price: $12.56
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -11,251
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,251
Exercise price: $12.56
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -80,250
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,250
Exercise price: $9.12
Footnotes: F1, F2, F5, F6

RAPT transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -69,271
Change %: -58%
Price
Shares after: 49,479
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,271
Exercise price: $7.43
Footnotes: F1, F2, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Rodney Kb Young is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the "Merger Agreement") with GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

Footnote F2

This Form 4 reports securities transacted pursuant to the Merger Agreement.

Footnote F3

The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.

Footnote F4

Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.

Footnote F5

The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.

Footnote F6

Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.

Footnote F7

Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a "2025 Option") was cancelled and converted into a cash-based award of Parent (a "Converted Option"), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the "Converted Option Consideration").

Footnote F8

Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the "Closing Date") and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.